Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation.
Development of a vaccine against Epstein-Barr virus (EBV) is constrained by the latency phenotypes adopted by different EBV-associated diseases. Over the last few years an immense body of information on the pattern of viral gene expression in EBV-associated diseases and the role of cytotoxic T cells in the control of these diseases has accumulated. It would seem reasonable to suggest that emerging technologies are at a level where vaccine trials aimed at controlling infectious mononucleosis, post-transplant lymphoproliferative disease, nasopharyngeal carcinoma and Hodgkin's disease are justified. On the other hand, a more cautious approach may be required for the development of vaccines or immunotherapeutic strategies against Burkitt's lymphoma.
Khanna
R
R
Tumour Immunology Laboratory, Epstein-Barr Virus Unit, Queensland Institute of Medical Research and Joint Oncology Program, University of Queensland, Bancroft Centre, Herston, Australia. rajivK@qimr.edu.au
Moss
D J
DJ
Burrows
S R
SR
D000818:Animals; D000956:Antigens, Viral; D002051:Burkitt Lymphoma / Q000276:immunology / Q000628:therapy; D004195:Disease Models, Animal; D020031:Epstein-Barr Virus Infections / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D004854:Herpesvirus 4, Human / Q000235:genetics / Q000276:immunology / Q000472:pathogenicity; D006801:Humans; D007167:Immunotherapy; D007231:Infant, Newborn; D007244:Infectious Mononucleosis / Q000276:immunology / Q000517:prevention & control; D051379:Mice; D010641:Phenotype; D011323:Primates; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014765:Viral Vaccines / Q000494:pharmacology*
D000956:Antigens, Viral; D014765:Viral Vaccines